If the three initial public offerings to price late last week – Pacira Pharmaceuticals Inc., Endocyte Inc. and BG Medicine Inc. – are a promising sign for the U.S. IPO market, then perhaps Italian biotech Philogen SpA's plans for a €65.3 million (US$89.6 million) offering on the Milan stock exchange is a signal the European markets are opening up as well.